Head to Head Review: BioHarvest Sciences (BHST) vs. The Competition

BioHarvest Sciences (NASDAQ:BHST) is one of 1,068 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare BioHarvest Sciences to similar companies based on the strength of its valuation, risk, analyst recommendations, dividends, profitability, earnings and institutional ownership.

Profitability

This table compares BioHarvest Sciences and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioHarvest Sciences	-76.65%	N/A	-85.16%
BioHarvest Sciences Competitors	-3,409.82%	-235.83%	-32.89%

Volatility and Risk

BioHarvest Sciences has a beta of 2.65, indicating that its stock price is 165% more volatile than the S&P 500. Comparatively, BioHarvest Sciences’ rivals have a beta of 3.66, indicating that their average stock price is 266% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for BioHarvest Sciences and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioHarvest Sciences	0	0	2	0	3.00
BioHarvest Sciences Competitors	8165	21842	49701	1311	2.55

BioHarvest Sciences currently has a consensus price target of $13.00, suggesting a potential upside of 150.48%. As a group, “Pharmaceutical preparations” companies have a potential upside of 250.80%. Given BioHarvest Sciences’ rivals higher possible upside, analysts clearly believe BioHarvest Sciences has less favorable growth aspects than its rivals.

Institutional and Insider Ownership

44.1% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 13.6% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares BioHarvest Sciences and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BioHarvest Sciences	$22.43 million	-$12.56 million	-4.15
BioHarvest Sciences Competitors	$9.97 billion	$135.94 million	-7.29

BioHarvest Sciences’ rivals have higher revenue and earnings than BioHarvest Sciences. BioHarvest Sciences is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

BioHarvest Sciences rivals beat BioHarvest Sciences on 8 of the 13 factors compared.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.